Plans to build a long-promised biological manufacturing facility in Manhattan have fizzled, though company leaders prefer not ...

(“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced the implementation of strategic cost-saving measures expected to save over $2 million annual ...

Aims to accelerate the lead candidate’s journey toward clinical success and expand its reach to patients who need it.

Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programsDURHAM, N.C., Jan. 22, 2025 (GLOBE ...

Both companies are also exploring a potential commercial-scale manufacturing agreement, reinforcing Scorpius's role as a reliable biomanufacturing partner. KaloCyte is advancing towards clinical ...

While K-State and the USDA loom large, the anchor tenant and a key force in Manhattan's bio-hub ambitions is the San Antonio-based third-party contractor Scorpius BioManufacturing. The company ...

Scorpius Holdings (SCPX) announced that the company’s planned 1-for-20 reverse stock split of its common stock that was announced yesterday, ...

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a groundbreaking advancement ...

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a ...

Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO") ...